CDKN2A and breast cancer: It has been shown that the promoter methylation of MGMT and BRCA-1 were higher in malignant breast tumor (MBT) compared with benign breast tumor (BBT) cases, while the P16 promoter methylation was lower in MBT patients compared with BBT.